Pyxis Oncology Inc. (PYXS)
| Bid | 1.19 |
| Market Cap | 71.36M |
| Revenue (ttm) | 19.16M |
| Net Income (ttm) | -56.18M |
| EPS (ttm) | -1.06 |
| PE Ratio (ttm) | -1.13 |
| Forward PE | -1.2 |
| Analyst | Buy |
| Ask | 1.2 |
| Volume | 412,224 |
| Avg. Volume (20D) | 876,208 |
| Open | 1.13 |
| Previous Close | 1.13 |
| Day's Range | 1.11 - 1.22 |
| 52-Week Range | 1.11 - 6.79 |
| Beta | 1.07 |
About PYXS
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...
Analyst Forecast
According to 6 analyst ratings, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 733.33% from the latest price.
2 months ago · seekingalpha.com
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts AheadPyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with...